

References

Cover Story—Barry Marshall: Curing Peptic Ulcers

1. Hardy J Medical wisdom challenged by a cocktail. *MicroBytes Newsletter*; available from: <https://hardydiagnostics.com/microbytes-newsletter>.
2. Marshall, B. J. (December 8, 2005) *Helicobacter* connections, In *The Nobel Prizes 2005* (Karl Grandin, ed) pp 250–277, Nobel Foundation, Stockholm; available from: <https://www.nobelprize.org/uploads/2018/06/marshall-lecture.pdf>.
3. Blaser, M. J. (February 1996) The bacteria behind ulcers. *Scientific American* **274(2)**: 104–107.
4. Lynch, N. A. (1998) *Helicobacter pylori* and ulcers: A paradigm revised. *Breakthroughs in Bioscience*; available from: <https://cidta.usal.es/cursos/enfermedades/modulos/libros/UNIDAD5/H.%20pylori.pdf>.
5. Kidd, M. and Modlin, I. M. (1998) A century of *Helicobacter pylori*: Paradigms lost—paradigms regained. *Digestion* **59**: 1–15.
6. Weintraub, P. (March 2010) The Discover interview: Barry Marshall. *Discover Magazine*, pp 66–74; available from: <https://www.discovermagazine.com/health/the-doctor-who-drank-infectious-broth-gave-himself-an-ulcer-and-solved-a-medical-mystery>.
7. Marshall, B. J. (2005) Biographical. NobelPrize.org; available from: <https://www.nobelprize.org/prizes/medicine/2005/marshall/biographical>.
8. Scheindlin, S. (2005) A century of ulcer medicines. *Molecular Interventions* **5(4)**: 201–206.
9. Rosenwald, M. S. (August 9, 2024) J. Robin Warren, who proved that bacteria cause ulcers, dies at 87. *New York Times*; available from: <https://www.nytimes.com/2024/08/09/health/j-robin-warren-dead.html>.
10. Medical Letter (January 15, 2018) Peptic Ulcer Disease. *Medical Letter* **60(1538)**: 10–16.
11. Inoue, M. and Tsugane, S. (2005) Epidemiology of gastric cancer in Japan. *Postgrad Med J* **81**: 419–424.
12. Warren, J. R. (December 8, 2005) Nobel Lecture: *Helicobacter*—the ease and difficulty of a new discovery; available from: <https://www.nobelprize.org/uploads/2018/06/warren-lecture.pdf>.
13. Marshall, B. J. and Warren, J. R. (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *The Lancet* **323(8390)**: 1311–1315.
14. Marshall, B. J., McGeachie, D. B., Rogers, P. A., and Glancy, R. J. (1985) Pyloric *campylobacter* infection and gastroduodenal disease. *Med J Australia* **142**: 439–444.
15. Warren, J. R. (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *The Lancet* **321(8336)**: 1273.
16. Marshall, B. (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *The Lancet* **321(8336)**: 1273–5.
17. Marshall, B. J., Warren, J. R., Blincow, E. D., Phillips, M., Goodwin, C. S., Murry, R., Blackbourn, S. J., Waters, T. E., and Sanderson, C. R. (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of *Campylobacter pylori*. *The Lancet* **332(8626–8627)**: 1437–1442.
18. Marshall, B. J., Armstrong, J. A., McGeachie, D. B., and Glancy, R. J. (1985) Attempt to fulfil Koch's postulates for pyloric *campylobacter*. *Med J Australia* **142**: 436–439.
19. Marshall, B. and Adams, P. C. (2008) *Helicobacter pylori*: A Nobel pursuit? *Can J Gastroenterol* **22(11)**: 895–896.
20. Medical Letter (July 17, 2017) Drugs for *Helicobacter pylori* infection. *Medical Letter* **59(1525)**: 113–117.
21. Wroblewski, L. E., Peek, R. M., Jr., and Wilson, K. T. (2010) *Helicobacter pylori* and gastric cancer: Factors that modulate disease risk. *Clin Microbiol Rev* **23(4)**: 713–739.
22. Morris, A. and Nicholson, G. (1987) Ingestion of *Campylobacter pyloridis* causes gastritis and raised fasting gastric pH. *Am J Gastroenterol* **82(3)**: 192–199.
23. Normile, D. (2024) Eliminating a gut microbe could slash gastric cancer. *Science* **385(6709)**: 585–586.
24. Yashima, K., Shabana, M., Kurumi, H., Kawaguchi, K., and Isomoto, H. (2022) Gastric cancer screening in Japan: a narrative review. *J Clin Med* **11**: 4337. <https://doi.org/10.3390/jcm11154337>.
25. Yamada, T., Searle, J. G., Ahnen, D., et al. (1994) *Helicobacter pylori* in peptic ulcer disease. *JAMA* **272(1)**: 65–69.
26. Han, D. H. (September 22, 2017) Best practice recs for *H pylori* treatment reviewed. *Medical Professionals Reference*; available from: <https://www.empr.com/home/news/best-practice-recs-for-h-pylori-treatment-reviewed>.
27. Duffy, S. (December 4, 2018) Novel *H pylori* eradication therapy effective in Phase 3 trial. *Medical Professionals Reference*; available from: <https://www.empr.com/home/news/drugs-in-the-pipeline/novel-h-pylori-eradication-therapy-effective-in-phase-3-trial>.
28. Medical Letter (June 1, 2020) Talicia—a 3-drug combination for *Helicobacter pylori* infection. *Medical Letter* **62(1599)**: 83–85.
29. Xie, X., Ren, K., Zhou, Z., Dang, C., and Zhang, H. (2022) The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. *BMC Gastroenterology* **22(1)**: 58. <https://doi.org/10.1186/s12876-022-02130-2>.

Advocacy Impact—Addressing the Divide: Examining Racial Disparities in Maternal Mortality

1. Hoyert, D. L. Maternal mortality rates in the United States, 2021. *NCHS Health E-Stats*. 2023. DOI: <https://dx.doi.org/10.15620/cdc:124678>.
2. National Partnership for Women & Families. (2019, October). American Indian and Alaska Native Women's Maternal Health: Addressing the Crisis. <https://nationalpartnership.org/wp-content/uploads/2023/02/american-indian-and-alaska.pdf>.
3. USAFacts. (2023a, May 15). Which states have the highest maternal mortality rates? *USAFacts*. <https://usafacts.org/articles/which-states-have-the-highest-maternal-mortality-rates>.
4. Trost, S. L., Beauregard, J., Njie, F., et al. Pregnancy-Related Deaths Among American Indian or Alaska Native Persons: Data from Maternal Mortality Review Committees in 36 US States, 2017–2019. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022.
5. NPR. (2017, December). Discrimination in America: Experiences and views of American women. <https://www.hsph.harvard.edu/wp-content/uploads/sites/21/2017/12/NPR-RWJF-HSPH-Discrimination-Women-Final-Report.pdf>.
6. Vedam, S., Stoll, K., Taiwo, T. K., et al. The Giving Voice to Mothers study: inequity and mistreatment during pregnancy and childbirth in the United States. *Reprod Health* 16, 77 (2019). <https://doi.org/10.1186/s12978-019-0729-2>.
7. Centers for Disease Control and Prevention. (2023, September). Racial/Ethnic Disparities in Pregnancy-Related Deaths—United States, 2007–2016. <https://archive.cdc.gov/www.cdc.gov/reproductivehealth/maternal-mortality/disparities-pregnancy-related-deaths/Infographic-disparities-pregnancy-related-deaths-h.pdf>.
8. Institute of Medicine. 2003. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: *The National Academies Press*. <https://doi.org/10.17226/12875>.
9. Centers for Disease Control and Prevention. (2022a, September 19). Four in 5 pregnancy-related deaths in the U.S. are preventable. <https://www.cdc.gov/media/releases/2022/p0919-pregnancy-related-deaths.html>.
10. Trost, S. L., Beauregard, J., Njie, F., et al. Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States, 2017–2019. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022.
11. Ranji, U., Gomez, I., Salganicoff, A., Rosenzweig, C., Kellenberg, R., & Gifford, K. (2022, May 19). Medicaid coverage of pregnancy-related services: Findings from a 2021 state survey—appendices—9936. *KFF*. <https://www.kff.org/report-section/medicaid-coverage-of-pregnancy-related-services-findings-from-a-2021-state-survey-appendices>.
12. Eliason, Erica L. Adoption of Medicaid Expansion Is Associated with Lower Maternal Mortality. *Women's Health Issues*, Volume 30, Issue 3, 147–152.

Advocacy Impact—Are ‘Forever Chemicals’ a Forever Problem? A Call for Increased PFAS Regulations in Consumer Products

1. Nutrition, C. for F. S. and A. Per- and Polyfluoroalkyl Substances (PFAS). *FDA* 2024.
2. Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS). *National Institute of Environmental Health Sciences*. <https://www.niehs.nih.gov/health/topics/agents/pfc> (accessed 2024-04-26).
3. Brennan, N. M., Evans, A. T., Fritz, M. K., Peak, S. A., von Holst, H. E. Trends in the Regulation of Per- and Polyfluoroalkyl Substances (PFAS): A Scoping Review. *Int. J. Environ. Res. Public Health* 2021, 18 (20), 10900. <https://doi.org/10.3390/ijerph182010900>.
4. EWG. Interactive Map: PFAS Contamination Crisis: New Data Show 5,021 Sites in 50 States. http://www.ewg.org/interactive-maps/pfas_contamination (accessed 2024-04-26).
5. Andrews, D. Q., Naidenko, O. V. Population-Wide Exposure to Per- and Polyfluoroalkyl Substances from Drinking Water in the United States. *Environ. Sci. Technol. Lett.* 2020, 7 (12), 931–936. <https://doi.org/10.1021/acs.estlett.0c00713>.
6. Potential health effects of PFAS chemicals | ATSDR. <https://www.atsdr.cdc.gov/pfas/health-effects/index.html> (accessed 2024-04-26).
7. US EPA, O. National Primary Drinking Water Regulations. <https://www.epa.gov/ground-water-and-drinking-water/national-primary-drinking-water-regulations> (accessed 2024-04-26).
8. US EPA, O. PFAS Strategic Roadmap: EPA's Commitments to Action 2021-2024. <https://www.epa.gov/pfas/pfas-strategic-roadmap-epas-commitments-action-2021-2024> (accessed 2024-04-26).
9. Regulations, Laws & Standards. U.S. Consumer Product Safety Commission. <https://www.cpsc.gov/Regulations-Laws--Standards> (accessed 2024-04-26).